People who take a commonly-prescribed drug for inflammatory bowel disease (IBD) should not assume they are protected after a first dose of COVID-19 vaccine, after a large-scale study found many had poor antibody responses.
People who take a commonly-prescribed drug for inflammatory bowel disease (IBD) should not assume they are protected after a first dose of COVID-19 vaccine, after a large-scale study found many had poor antibody responses.